Commission reports on latest patent settlements in the pharma sector
The European Commission today published its seventh monitoring report on pharmaceutical patent settlements.
The report covers the 125 patent settlements concluded between originator and generic companies in the pharmaceutical sector in 2015. This number is higher than in 2014 (76) and is closer to the higher numbers seen in 2012 (183) and 2013 (146), and remains significantly higher than the average of 24 in the period between 2000 and 2008.
The annual monitoring exercises since 2008 have shown that the Commission's enforcement activities in this area do not discourage companies from settling their patent disputes. The number of settlements that might attract competition law scrutiny has progressively decreased since the pharmaceutical sector inquiry in 2008 and has stabilized at a low level.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze